Citi: Maintains Buy rating on Hutchmed (China), Target Price raised to HKD 42.

Citi released a research report stating that it maintains a "Buy" rating for Hutchmed (China) (00013), with the Target Price raised from 38.9 HKD to 42 HKD. Additionally, the bank has lowered its revenue forecast for the company by 5% for this year and next year, considering the Trade with Shanghai Haijiao Pharmaceuticals, adjusting the forecasted earnings per share to 0.69 USD and 0.01 USD respectively. Hutchmed announced yesterday (the 2nd) that the new drug application for the combination therapy of Savolitinib (ORPATHYS) and Osimertinib (TAGRISSO) has been approved by the National Medical Products Administration.

新浪港股52minutes ago

Big Banks Flee Climate Coalition Formed to Reduce Carbon Emissions -- WSJ

WSJ23:00 ET

Citi: Assigns EAST BUY rating to EAST BUY with a Target Price of 18.5 HKD.

Citi released a research report stating that EAST BUY (01797) has seen its stock price increase by about 30% since December 19, primarily due to its early adoption of WeChat's newly launched "gift" feature in the WeChat store mini-program ecosystem. Target Price is HKD 18.5, with a rating of "Buy". The bank believes that EAST BUY is well-positioned to fully capitalize on the surge in seasonal gifting demand during the Spring Festival, for reasons including the company's potential to leverage the power of the WeChat social commerce platform; the first-mover advantage with the new gifting feature in WeChat's vast ecosystem; and WeChat's friendly measures to lower the technical service fee threshold from 5% to 2%.

Sina Hong Kong Stocks22:25 ET

Goldman Sachs Adds 3 Stocks To 'Conviction List,' Flags 5 Market Trends To Monitor In 2025

Benzinga16:59 ET

KBW Maintains Citigroup(C.US) With Buy Rating, Raises Target Price to $85

Moomoo News16:32 ET · Ratings

Bank of America, Citigroup Exit Climate Alliance As Trump Policies Shift Energy Priorities

Benzinga12:05 ET